This is a StreetInsider.com Premium Only Page

Cogent Biosciences (COGT) – StreetInsider.com Reports

Apr 1, 2024 03:17 AM Jefferies Assumes Cogent (COGT) at Buy, 'A Validated Tool "KIT" for Mast Cell Diseases & GI Cancer'

Feb 27, 2024 06:39 AM Cogent (COGT) PT Raised to $19 at H.C. Wainwright

Feb 26, 2024 09:24 AM Cogint (COGT) Misses Q4 EPS by 7c

Feb 26, 2024 04:22 AM Baird Downgrades Cogent (COGT) to Neutral, 'fairly valued around these levels'

Feb 26, 2024 02:58 AM Cogent (COGT) PT Raised to $13 at Citi

Feb 23, 2024 07:33 AM Cogent (COGT) PT Raised to $18 at Needham & Company

Feb 22, 2024 02:30 PM Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Feb 14, 2024 07:04 AM Cogent Biosciences (COGT) Announces Oversubscribed $225M Private Placement

Feb 8, 2024 04:16 AM Citi Starts Cogent (COGT) at Buy

Dec 26, 2023 04:59 AM Cogent Biosciences (COGT) January calls and puts active

Dec 15, 2023 06:42 AM Cogent (COGT) PT Lowered to $13 at H.C. Wainwright

Dec 12, 2023 07:15 AM Cogent (COGT) PT Lowered to $14 at Baird

Dec 11, 2023 12:49 PM Wedbush Downgrades Cogent (COGT) to Neutral

Dec 11, 2023 08:42 AM Cogent Biosciences (COGT) Declines 40% Following Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with AdvSM

Dec 11, 2023 07:55 AM Cogent Biosciences (COGT) Reports Positive Data from Ongoing Phase 2 APEX Trial of Bezuclastinib

Dec 11, 2023 04:00 AM Cogent Biosciences (COGT) Reports Positive Initial Data from Phase 2 SUMMIT Trial of Bezuclastinib

Dec 8, 2023 04:41 AM JPMorgan Starts Cogent (COGT) at Overweight

Dec 7, 2023 09:05 AM Cogent Biosciences (COGT) Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs

Jun 8, 2023 06:32 AM Cogent (COGT) PT Lowered to $27 at H.C. Wainwright

Jun 7, 2023 05:15 AM Cogent Biosciences (COGT) Prices 12.5M Share Offering at $12/sh

Jun 6, 2023 05:24 PM After-hours movers: Yext jumps following earnings, Couchbase falls

Jun 6, 2023 04:06 PM Cogent Biosciences (COGT) Announces Proposed $125M Share Offering

Jun 5, 2023 05:56 AM Cogent Biosciences (COGT) Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial of Bezuclastinib with Sunitinib

Apr 28, 2023 08:35 AM Baird Starts Cogent (COGT) at Outperform, Says '$16/share of our $20 price target to bezuclastinib for non-advanced SM'

Apr 17, 2023 09:01 AM Cogent Biosciences (COGT) Presents Preclinical Data

Mar 27, 2023 06:09 AM H.C. Wainwright Assumes Cogent (COGT) at Buy

Mar 15, 2023 07:11 AM Cogent (COGT) PT Lowered to $23 at Needham & Company

Jan 9, 2023 08:19 AM Cogent Biosciences (COGT) Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics

Dec 20, 2022 12:01 PM 2023 may be the year of the Smid cap in biotech - Piper Sandler

Dec 14, 2022 06:30 AM Needham & Company Starts Cogent (COGT) at Buy

Dec 12, 2022 03:05 PM Cogent (COGT) PT Raised to $24 at Guggenheim

Dec 12, 2022 06:49 AM Cogent Biosciences (COGT) announces positive data update from Phase 2 APEX trail of bezuclastinib in AdvSM

Jun 28, 2022 07:09 AM UPDATE: Guggenheim Starts Cogent (COGT) at Buy

Jun 17, 2022 09:00 AM Cogent (COGT) Reiterated Top Pick at Piper Sandler as Financing Offers Visibility into '25

Jun 14, 2022 06:59 AM Cogent Biosciences (COGT) Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants

Jun 13, 2022 02:49 PM Cogent Biosciences (COGT) Trades at High, Up 27%

Jun 13, 2022 06:01 AM Cogent Biosciences (COGT) Announces $125M Share Offeirng

Jun 10, 2022 12:06 PM SVB Leerink Reiterates Outperform Rating on Cogent (COGT), 'We believe that the bezuclastinib dataset will be a meaningful catalyst for shares'

Jun 10, 2022 12:05 PM Piper Sandler Reiterates Overweight Rating on Cogent (COGT), 'Start Calling it Best-in-Class-tinib', Shares Continue Triple-Digit Climb

Jun 10, 2022 11:36 AM Cogent Biosciences (COGT) Extends Gain, Now Up 100%

Jun 10, 2022 09:20 AM Cogent Biosciences (COGT) Climbs 33% Following Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial

Jun 10, 2022 07:01 AM Cogent Biosciences (COGT) Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis

May 9, 2022 05:59 AM Cogent Biosciences (COGT) Files Mixed Shelf Registration Statement

Jan 5, 2022 07:02 AM Cogent Biosciences (COGT) Issues 2022 Guidance

Nov 5, 2021 01:13 PM Cogent (COGT) PT Raised to $31 at H.C. Wainwright

Oct 11, 2021 06:43 AM UPDATE: H.C. Wainwright Starts Cogent (COGT) at Buy

Aug 16, 2021 12:33 PM Cogent (COGT) PT Lowered to $19 at Wedbush, Following Earnings

Jul 21, 2021 11:48 AM Cogent Biosciences (COGT) gains FDA Orphan Drug Designation for Treatment of gastrointestinal stromal tumors

Jun 9, 2021 07:44 AM Jefferies Assumes Cogent (COGT) at Buy, $20 PT

May 12, 2021 01:49 PM Cogent (COGT) PT Raised to $24 at Wedbush, Following Earnings